Artivion's medical device franchise carries analyst consensus targets implying more than 73% upside from current levels and a risk/reward ratio of roughly 10-to-1 in favor of the bull case, but the near-term picture is complicated by a recent 35% earnings miss, free cash flow that is negative relative to net income, a confirmed price downtrend, and eight disclosed supplier concentration vulnerabilities including sole manufacturers for key product families.
Thesis pillars
- Large Consensus Implied Upside→Stable
- Above Peer Growth Profile→Stable
- Negative Free Cash Flow Risk→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 18, 2026
Artivion, Inc. (AORT) Stock Analysis
Recovery setup
Healthcare · Medical Devices
Sell if holding. Momentum 4.2/10 is below the 5.0 floor at $22.92 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: Endospan (NEXUS family); Concentration risk — Supplier: AMDS sole manufacturer.
Artivion manufactures medical devices and processes implantable human tissues for cardiac and vascular surgery, with segments spanning Medical Devices (aortic stent grafts, On-X valves, BioGlue sealant) and Preservation Services. Products are sold globally across North America,... Read more
Sell if holding. Momentum 4.2/10 is below the 5.0 floor at $22.92 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: Endospan (NEXUS family); Concentration risk — Supplier: AMDS sole manufacturer. Chart setup: Death cross but MACD improving, RSI 66. Score 5.2/10, moderate confidence.
Passes 4/8 gates (favorable risk/reward ratio, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 7d<=7d. Suitability: speculative.
Recent developments
updated 2026-10-29Recent Developments — Artivion, Inc.
Latest news
- NEWS Why Artivion (AORT) Stock Is Trading Up Today - Yahoo Finance — Yahoo Finance positive
- NEWS Summit Creek Advisors LLC Takes Position in Artivion, Inc. $AORT - MarketBeat — MarketBeat neutral
- NEWS Jean Holloway Sells 977 Shares of Artivion (NYSE:AORT) Stock - MarketBeat — MarketBeat negative
- NEWS Artivion (AORT) Is Up 5.5% After FDA AMDS Approval And Reaffirmed 2026 Revenue Guidance - What's Changed - simplywall.st — simplywall.st positive
- NEWS Artivion Inc (AORT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey — TradingKey neutral
Generated 2026-10-29T11:53:50Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierEndospan (NEXUS family)10-K Item 1A: 'the NEXUS family of products are solely manufactured by Endospan in Herzliya, Israel'
- HIGHSupplierAMDS sole manufacturer10-K Item 1A: 'The AMDS product is solely manufactured by a supplier in Charlotte, North Carolina'
- HIGHSupplierBioGlue single-supplier delivery devices10-K Item 1A: 'We are significantly dependent on our revenues from BioGlue ... The delivery devices are manufactured by a single supplier, using resin supplied by a different single supplier'
- HIGHSupplierOn-X AAP single-supplier grafts10-K Item 1A: 'We purchase grafts for our On-X AAP from a single supplier'
- MEDIUMProductBioGlue10-K Item 1A: 'BioGlue is a significant source of our revenues'
- MEDIUMProductOn-X products10-K Item 1A: 'On-X products are a significant source of our revenues'
- MEDIUMProductaortic stent grafts10-K Item 1A: 'Aortic stent grafts are a significant source of our revenues'
- MEDIUMProducttissue preservation services10-K Item 1A: 'Tissue preservation services are a significant source of our revenues'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 4.2/10 is below the 5.0 floor at $22.92 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Supplier: Endospan (NEXUS family); Concentration risk — Supplier: AMDS sole manufacturer. Chart setup: Death cross but MACD improving, RSI 66. Prior stop was $21.32. Score 5.2/10, moderate confidence.
Analyst target: $35.59 (+55.3% upside). Prior stop was $21.32. Stop-loss: $21.32.
Concentration risk — Supplier: Endospan (NEXUS family); Concentration risk — Supplier: AMDS sole manufacturer; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.7).
Artivion, Inc. trades at a P/E of N/A (forward 30.6). TrendMatrix value score: 6.3/10. Verdict: Sell.
14 analysts cover AORT with a consensus score of 4.3/5. Average price target: $41.
What does Artivion, Inc. do?Artivion manufactures medical devices and processes implantable human tissues for cardiac and vascular surgery, with...
Artivion manufactures medical devices and processes implantable human tissues for cardiac and vascular surgery, with segments spanning Medical Devices (aortic stent grafts, On-X valves, BioGlue sealant) and Preservation Services. Products are sold globally across North America, EMEA, APAC, and LATAM from facilities in Georgia, Texas, and Germany. BioGlue, On-X products, aortic stent grafts, and tissue preservation services are each individually characterized as significant revenue sources.